Sugi Predict

Sugi Predict / Compounds / SCHEMBL695608

SCHEMBL695608

SCHEMBL695608

CCCCOC(=O)N1CCCC1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 1/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ LMNA P02545 2/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ ACE P12821 9/20 0.48
▸ ACE2 Q9BYF1 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ REN P00797 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ F2 P00734 1/20 0.46
▸ LTA4H P09960 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ PEPD P12955 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ PTGS1 P23219 1/20 0.46
▸ HTR2A P28223 1/20 0.46
▸ PTGS2 P35354 1/20 0.46
▸ HRH1 P35367 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5493674 1.00 RAB9A (0.62) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL2634067 1.00 RAB9A (0.62) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL9464451 0.98 RAB9A (0.61) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL18209676 0.96 RAB9A (0.58) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL7815566 0.95 RAB9A (0.57) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL7811720 0.95 RAB9A (0.57) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL16124534 0.95 RAB9A (0.61) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL3710312 0.95 RAB9A (0.57) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL18106053 0.94 RAB9A (0.57) RAB9AL3MBTL1LMNAHSD17B10CYP2C19
SCHEMBL7771246 0.94 RAB9A (0.59) RAB9AL3MBTL1LMNAHSD17B10CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365594-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
WO-2023205618-A2 CCR4 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2023-10-26 — — WO disclosed
WO-2023154962-A1 CGAS INHIBITORS AND USES THEREOF SINHA SUBHASH (US) 2023-08-17 — — WO disclosed
US-11661431-B2 Thienopyrrole compounds GILEAD SCIENCES, INC. (US) 2023-05-30 — — US disclosed
US-20220389034-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2022-12-08 — — US disclosed
WO-2022165185-A9 CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2022-12-01 — — WO disclosed
EP-3999064-A1 INHIBITORS OF TYROSINE KINASE Bridgene Biosciences, Inc. (US) 2022-05-25 — — EP disclosed
WO-2021016102-A1 INHIBITORS OF TYROSINE KINASE BRIDGENE BIOSCIENCES, INC. (US) 2021-01-28 — — WO disclosed
EP-3649106-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-05-13 — — EP disclosed
WO-2019008506-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-10 — — WO disclosed
WO-2009102325-A1 IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-20 — — WO disclosed
EP-1628970-A2 HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B The Institutes of Pharmaceutical Discovery, LLC (US) 2006-03-01 — — EP disclosed
WO-2005116058-A1 PEPTIDES USEFUL FOR TREATING GNRH ASSOCIATED DISEASES CUREPEPTIDE LTD. (IL) 2005-12-08 — — WO disclosed
WO-2004099192-A2 HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B THE INSTITUTES OF PHARMACEUTICAL DISCOVERY, LLC (US) 2004-11-18 — — WO disclosed
EP-0975560-A4 CHIRAL SEPARATIONS OF AMINO ACIDS CHIRAL TECHNOLOGIES INC (US) 2004-10-06 — — EP disclosed
EP-0994848-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-04-26 — — EP disclosed
EP-0975560-A1 CHIRAL SEPARATIONS OF AMINO ACIDS Chiral Technologies, Inc. (US) 2000-02-02 — — EP disclosed
WO-1999001423-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 1999-01-14 — — WO disclosed
WO-1998041489-A1 CHIRAL SEPARATIONS OF AMINO ACIDS CHIRAL TECHNOLOGIES, INC. (US) 1998-09-24 — — WO disclosed
US-5079357-A Bactericides DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1992-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365594-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 RAB9A 2741/4885L3MBTL1 3714/4885LMNA 1961/4885
US-11661431-B2 Thienopyrrole compounds SSB, TPMT, LCP2 RAB9A 2741/4885L3MBTL1 3714/4885LMNA 1961/4885
US-20220389034-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 RAB9A 2741/4885L3MBTL1 3714/4885LMNA 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.